Literature DB >> 6624010

A competitive inhibition assay for gelatin binding fibronectin.

J E Doran, B D Callaway, A C Reese, J J Wynn, A R Mansberger.   

Abstract

A competitive inhibition assay for functional fibronectin (Fn), based on ELISA technology, is described. The assay measures Fn's physiologic ability to bind to denatured collagen (gelatin). Affinity-purified Fn inhibits the binding of alkaline phosphatase coupled Fn to gelatin-coated wells of a microtiter plate in a concentration-dependent manner. The assay range is 50-500 micrograms Fn/ml, which is suitable for the measurement of plasma Fn in both normal and opsonin deficient individuals. It is reproducible over an eightfold dilution of plasma and is resistant to interference by normal plasma proteins. The assay described is quick, quantitative, and reproducible, and satisfies the need for a measure of functional Fn activity in the clinical laboratory.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6624010     DOI: 10.1111/j.1423-0410.1983.tb01910.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

1.  The influence of fibronectin administration on the incidence of sepsis and septic mortality in severely injured patients. The Medical College of Georgia Fibronectin Research Group.

Authors:  A R Mansberger; J E Doran; R Treat; M Hawkins; J R May; B D Callaway; M Horowitz; B Horowitz; R Shulman
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

Review 2.  Plasma fibronectin: relevance for anesthesiology and intensive care.

Authors:  J E Doran; P Lundsgaard-Hansen; E Rubli
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

3.  Purified fibronectin administration to patients with severe abdominal infections. A controlled clinical trial.

Authors:  P Lundsgaard-Hansen; J E Doran; E Rubli; E Papp; J J Morgenthaler; P Späth
Journal:  Ann Surg       Date:  1985-12       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.